Scopus (SJR) / WoS (JCR)
Istanbul Medical Journal
WoS (JCR)
Q4
JIF 0,2
2023 yılı
Makale detayı · 2023
A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
İstanbul Medical Journal
YÖKSİS
OpenAlex
ISSN 2619-9793
DOI 10.4274/imj.galenos.2023.66742
Atıf 1
Açık erişim · diamond
JCR Q4
TR Index
10.4274/imj.galenos.2023.66742
YÖKSİS YÖKSİS makale kaydı
OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex kaydıİngilizce (OpenAlex)
Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: 35%) by imaging and control of hematocrit levels (45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman's rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman's rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher's exact test: p=0.033).
İndeks bilgisi
WoS (JCR) ve Scopus (SJR) çeyrekleri ISSN ve yayın yılına göre. · 2023
TR Index
İstanbul Medical Journal
TR Index yılları 2013–2026 (14)
Makale yılı TR Index kapsamında.
Üniversiteler
- ALTINBAŞ ÜNİVERSİTESİ
- NECMETTİN ERBAKAN ÜNİVERSİTESİ